Revolution Medicines, Inc. RVMD Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $343.97M+16.6% | $294.94M+12.4% | $262.51M+17.1% | $224.13M+8.9% | $205.75M+9.4% | ||
| $101.25M+51.8% | $66.68M+26.4% | $52.76M+30.0% | $40.58M+15.9% | $35.01M+24.1% | ||
| $445.22M+23.1% | $361.63M+14.7% | $315.27M+19.1% | $264.71M+9.9% | $240.76M+11.3% | ||
| -$445.22M-23.1% | -$361.63M-14.7% | -$315.27M-19.1% | -$264.71M-9.9% | -$240.76M-11.3% | ||
| $12.2M+2.2% | $11.94M+4.4% | $11.43M+1,218% | $867K— | $0— | ||
| -$8.59M— | $0-100% | $10.06M-40.6% | $16.93M-38.1% | $27.34M+30.3% | ||
| -$453.82M-24.4% | -$364.89M-19.6% | -$305.21M-23.2% | -$247.79M-16.1% | -$213.42M-9.3% | ||
| -$453.82M-24.4% | -$364.89M-19.6% | -$305.21M-23.2% | -$247.79M-16.1% | -$213.42M-9.7% | ||
| -$2.29-21.2% | -$1.89-17.4% | -$1.61-22.9% | -$1.31-15.9% | -$1.130.0% | ||
| -$442.88M-23.2% | -$359.36M-14.7% | -$313.21M-19.1% | -$262.96M-10.0% | -$239.07M-11.4% | ||
| -$445.22M-23.1% | -$361.63M-14.7% | -$315.27M-19.1% | -$264.71M-9.9% | -$240.76M-11.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Revolution Medicines, Inc. profitable?
- Revolution Medicines, Inc. is not currently profitable: it reported a net loss of $1.4B over the trailing twelve months, a -76423.3% net margin.
- What is Revolution Medicines, Inc.'s earnings per share?
- Revolution Medicines, Inc.'s diluted EPS over the trailing twelve months is $-7.10.
- Where does Revolution Medicines, Inc.'s income statement data come from?
- Every line is extracted from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.